HER2−, HR+ early breast cancer: are anthracyclines necessary?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • Previous data suggest that cardiotoxic anthracyclines (doxorubicin [Adriamycin] & epirubicin [Ellence]) may have limited value in human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC).
  • This phase 3 trial in patients with HER2-negative, hormone receptor-positi...